MissionIR Articles
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) on Leading Edge of Development of Psychedelics as Public Support Grows
More than 60% of American who suffer from mental health conditions want access to psychedelic options Growing number of cities, states looking at decriminalizing use of psychedelic medicine Cybin is working with world-class partners, internationally…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Upcoming Maxim Group Virtual Growth Conference
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM) is planning to participate in the 2022 Virtual Growth Conference. The conference is slated for March 28–30, 2022, from 9 a.m.…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Eyes Potential of First-of-Its-Kind Study
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), recently secured approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics
Psychedelic drugs are on cusp of entering mainstream treatment for mental illness Cybin, Chopra Foundation to collaborate on efforts aimed to support education, awareness about psychedelic therapy mental health research Cybin “one of the only…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted U.S. Patent for Deuterated DMT
Company announced the first officially issued patent Patent provides strong protection for Cybin’s growing IP portfolio of psychedelic-based compounds CYB004 has demonstrated potential efficacy at lower doses while increasing duration of drug effect that may…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Oppenheimer Annual Healthcare Conference
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its Chief Executive Officer Doug Drysdale will participate in a fireside chat at the Oppenheimer 32nd Annual…
-
MissionIRNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Feasibility Study to Potentially Open New Frontiers of Understanding Psychedelics
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its receipt of approval from an Institutional Review Board (“IRB”) for…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone
Cybin (NEO: CYBN) (NYSE American: CYBN),a biopharmaceutical company focused has announced that subsidiary Adelia Therapeutics Inc. has achieved a milestone outlined in the contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that its CEO Doug Drysdale will participate in a fireside chat at the Aegis Virtual Conference. The event…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has entered a strategic partnership with The Chopra Foundation, a not-for-profit organization founded by Dr. Deepak Chopra, dedicated to improving…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality
Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is on a mission to revolutionize mental health care. The company has developed key relationships with…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study
Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results…
-
MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The patent, granted by the U.S. Patent…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, accomplished a host of major milestones in 2021, proving it is on the right path to…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year
Upcoming study supports CYBN’s mission to develop psychedelics into therapeutics. Kernel Flow uses pulsed light instead of continuous wave light to increase measured brain information. Study may provide crucial “mind-imaging” information that has been previously…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Scheduled Release of Q3 Financial Results, Conference Call
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that it will report financial results for its third quarter ended Dec. 31, 2021, on Thursday, Feb. 10,…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend
Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health treatment” Cybin working to combine novel psychedelic molecules with controllable…
-
MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Strengthening ‘Emerging Best-in-Class Position’ in Evolving Industry
Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently received a notice of allowance from the U.S. Patent and Trademark Office (“USPTO”). The notice…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year
Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies…
-
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004
Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in…
Search Articles
Latest Articles
- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Advancing a Premier North American Copper District
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
- Safe Pro Group Inc. (NASDAQ: SPAI) Advanced AI Patent Protections with Notification Publications in Australia, Israel, and the European Region
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Prices $7 Million Public Offering of Common Stock and Pre-Funded Warrants